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1. Introduction  
Prostate cancer remains the most common non-cutaneous malignancy in the Western world 
and is the second leading cause of cancer death in males, after lung cancer (Nelson et al., 
2003; Papatsoris & Anagnostopoulos, 2009). Based on experimental and preclinical findings, 
novel anti-prostate cancer strategies have been developed (Papatsoris & Papavassiliou, 2001; 
Papatsoris et al., 2005). However, the causes of prostate cancer, prostatic carcinogenesis, and 
the histological changes preceding and leading to the initiation of prostate cancer have yet to 
be elucidated. Several research groups are trying to solve the puzzle of prostatic 
carcinogenesis by focusing within the morphological continuum between benign glands at 
one end and premalignant lesions and invasive disease at the other (Vis & Van Der Kwast, 
2001). In parallel, clinicians are frequently confronted with morphological features on the 
prostate needle biopsy that, although negative for cancer, raise suspicion of concomitant 
malignancy.  
2. Definition of prostate cancer precursor lesions 
There are several criteria that should be met in order to consider a prostatic lesion as 
premalignant (Vis & Van Der Kwast, 2001). An epidemiological relationship must be 
revealed, the precursor lesion should present at an earlier age than the cancer, and clear 
morphological similarities (e.g. cellular, histological, and architectural) should be present. 
Also, premalignant lesions should be close to their presumed malignant equivalents. The 
prostate has a greater frequency, severity, and extent of premalignant lesions in comparison 
with other organs. The definitive proof of a relationship between a premalignant lesion and 
malignancy is the clinical evidence of progression into invasive prostate cancer.  
The earliest report on premalignant prostatic lesions dates back to 1926 (Orteil, 1926). In 
1965, McNeal described lesions with possible premalignant features in prostatic epithelium 
(McNeal, 1965). In 1986, McNeal and Bostwick described the first criteria for the diagnosis of 
“intraductal neoplasia” which was classified into three grades (McNeal & Bostwick, 1986). 
In 1987, Bostwick and Brawer introduced the term “PIN” - prostatic intraepithelial neoplasia 
(Bostwick & Brawer, 1987). At an international conference in 1989, the term “PIN” was 
accepted as a replacement for various other terms (e.g. intraductal hyperplasia, hyperplasia 
with malignant change, large acinar atypical hyperplasia, marked atypia, ductal-acinar 
dysplasia). Initially, PIN was categorized into three grades with regard to architectural and 
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cytological characteristics, taking into account that the alterations cover a continuum. 
However, in 1989, at the aforementioned workshop on premalignant prostatic lesions, the 
classification was altered to low-grade (formerly grade I) and high-grade (formerly grades II 
and III) PIN - LGPIN and HGPIN, respectively (Bostwick, 1989). 
Conventional histopathology examination is used to differentiate precursor lesions of 
prostate cancer. Benign glands show a continuous basal cell layer, while in prostate cancer 
the basal cell layer is immunohistochemically absent. Immunostaining for p63 (a p53 
homologue) was shown to be useful as a basal cell-specific marker (Signoretti et al., 2000; 
Shah, 2004). It is frequently used in addition to 34┚E12 immunostaining in difficult 
diagnostic cases, where the main advantage of p63 over 34┚E12 is that there is less variable 
staining.  
A wide range of “atypical” epithelial proliferative processes with a variety of names, often 
with confusing and overlapping terminology, has been described. Several morphological 
lesions have been proposed that may act as potential precursor lesions of prostate cancer. 
These are the morphologically distinct entities of focal atrophy or post-atrophic hyperplasia 
(PAH), atypical adenomatous hyperplasia (AAH) or adenosis, and PIN. 
3. Prostatic atrophy and PAH 
Focal prostatic atrophy reportedly is present in up to 85% of prostates at autopsy (Amin, 
1999; Billis, 1998). It should be distinguished from diffuse atrophy, as the latter is not 
considered premalignant. A role for focal atrophy in the pathogenesis of PIN and/or 
prostate cancer was proposed by Franks, over 50 years ago (Franks, 1954). De Marzo 
observed that focal atrophic lesions showed an increased proliferative activity of luminal 
cells and a decreased frequency of apoptosis (DeMarzo et al., 1999). Concerning the 
classification of focal prostatic atrophy, although there are distinct histologic variants, the 
terminology is currently non-standardized and no formal classification has been tested for 
interobserver reliability. According to the current classification focal atrophy lesions were 
categorized into 4 distinct subtypes as follows: (i) simple atrophy, (ii) simple atrophy with 
cyst formation, (iii) postatrophic hyperplasia and (iv) partial atrophy (De Marzo et al., 2006). 
Simple atrophy consists of atrophic cells lining acini with relatively normal caliber that lack 
papillary fronds, where the number of glands per unit area does not appear to be increased 
relative to normal tissue. (De Marzo et al., 2006). Simple atrophy demonstrates strong basal 
cell-specific antikeratin immunoreactivity (Bostwick, 1996). Simple atrophy with cyst 
formation is a subtype of simple atrophy. Two general patterns are now encompassed: those 
containing very large diameter glands (> 1 mm) and those containing smaller, rounded 
glands. The amount of cytoplasm at times may be so attenuated as to be nearly invisible. 
When there is significant cytoplasm in the luminal cell, it tends to be clear. Atrophy with 
cyst formation tends to have less inflammation than the other sub-types (De Marzo et al., 
2006). In sclerotic atrophy, the stroma is more extensively sclerosed, resulting in a wider 
separation of the acinar elements; these continue to have the cytological features described 
above (DeMarzo et al., 1999; De Marzo et al., 2006). Post-Atrophic Hyperplasia (PAH) 
consists of acini that are smaller, round and appear in a lobular distribution, often 
surrounding a somewhat dilated duct with an apparent increase in the number of small 
glands compared to normal tissue. Some authors tend to refer to some of these lesions as 
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"lobular atrophy" or "lobular hyperplasia" (De Marzo et al., 2006). In lobular atrophy, the 
lesion is circumscribed with a central duct surrounded by small acini (Grignon & Sakr, 
1996). The acini frequently have ectatic lumens and are lined by a flattened epithelium 
having scant cytoplasm and hyperchromatic nuclei with inconspicuous nucleoli. Basal cells 
are present but are difficult to recognize; however, they are readily identified with 
immunohistochemical stains for 34┚E12 cytokeratin. The stroma is sclerotic and compressed, 
particularly around the central duct.  
PAH, which may closely mimic the histology of prostate cancer, may represent a diagnostic 
pitfall (Bostwick, 1996). Recent studies have reported that the frequency of PAH in radical 
prostatectomy specimens was remarkably similar to that in cystoprostatectomy specimens, 
implying that the simultaneous finding of PAH with prostate cancer is coincidental (Amin, 
1999; Grignon & Sak, 1996). PAH develops in a background of lobular or sclerotic atrophy 
and so retains many features of these lesions (Anton et al., 1999; Cheville & Bostwick, 1995; 
Grignon & Sakr, 1996). In PAH, there is an apparent secondary proliferation of small acini. 
The secretory cells have more abundant pale or clear cytoplasm than in usual atrophy, 
though generally not as much as in adenocarcinoma or AAH. The nuclei also become less 
hyperchromatic, and small chromocenters or nucleoli may be seen. The double cell layer is 
maintained and can be confirmed with basal cell-specific anticytokeratin antibodies. Despite 
the observation that focal atrophic lesions and PAH consist of flattened and dispersed acini, 
immunostaining with 34┚E12 cytokeratin is almost always positive and continuous, as it is 
for benign epithelial glands (Anton et al., 1999; Cheville & Bostwick, 1995). 
4. AAH and sclerosing adenosis 
The prevalence of AAH in transurethral prostatectomy (TURP) specimens without cancer 
ranges from 1.6% to 7.3% (Gaudi & Epstein, 1994). In biopsy specimens, the prevalence is 
lower, for example 0.8% in one series (Gaudin & Epstein, 1995). The increase in frequency of 
AAH in needle biopsies is presumably related to ultrasound-guided biopsy of the transition 
zone. AAH can be diagnosed throughout the prostate, but it is most often located in the 
transition zone of the prostate in intimate association with benign nodular hyperplasia 
(Bostwick & Qian, 1995). It can also be found near the apex and in the periurethral area 
(Bostwick, 1996). In AAH, the basal cell layer is discontinuous and fragmented on 34┚E12 
cytokeratin immunostaining (Cheng et al., 1998). 
There is considerable morphologic evidence suggesting that AAH is associated with low-
grade adenocarcinoma arising in the transition zone (Cheville & Bostwick, 1995). AAH, a 
putative precursor of transition zone adenocarcinoma, has common features with low-grade 
adenocarcinoma and may cause problems in differential diagnosis, especially in the needle 
biopsy setting (Srigley, 2004). AAH is a lesion characterized by a proliferation of small 
acinar structures that mimics adenocarcinoma because of histological similarities (Grignon 
& Sakr, 1996). At low magnification, the lesion is circumscribed, although the small acini 
may show some infiltrative features. These acini are seen in association with a usually 
hyperplastic nodule and are most often at the periphery of the nodule. The nuclei tend to be 
uniform and round with inconspicuous or small nucleoli. There is limited data that AAH 
has a proliferation rate higher than hyperplasia but lower than adenocarcinoma (Bostwick & 
Qian, 1995; Cheng et al., 1998; Grignon & Sakr, 1996). AAH is diploid, as are most examples 
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of low-grade adenocarcinoma, while a few markers (blood group antigens, peanut 
agglutinin) show similar patterns of expression in AAH and adenocarcinoma (Grignon & 
Sakr, 1996). Recent cytogenetic analyses have detected abnormalities of chromosome 8 in a 
very small proportion (4–7%) of AAH cases (Bostwick & Qian, 1995; Cheng et al., 1998). 
Sclerosing adenosis is a circumscribed proliferation of small acinar structures in a cellular 
spindled sclerotic stroma (Grignon & Sakr, 1996; Srigley, 2004). The acini range from 
irregular in shape to small, round, and uniform. Usually, there is thickening of the tubular 
basement membrane, a valuable diagnostic clue (Grignon & Sakr, 1996). Nucleoli are 
generally inconspicuous but can be prominent in a few cells, while the lumens can contain 
basophilic mucin or crystalloids (Grignon & Sakr, 1996). Sclerosing adenosis is usually an 
incidental finding in about 2% of transurethral resection of the prostate (TURP) or radical 
prostatectomy specimens, (Bostwick et al., 2008; Grignon et al., 1992; Cheng & Bostwick, 
2010; Sakamoto et al, 1991) and rarely is present in needle biopsy specimens (Cheng & 
Bostwick 2010; Srigley, 2004). Sclerosing adenosis may simulate adenocarcinoma and 
accounts for up to 10% of cases overdiagnosed as adenocarcinoma (Berney et al., 2007; 
Bostwick & Cheng, 1999; Cheng & Bostwick, 2010). Multiple light microscopic and 
immunohistochemical features separate typical sclerosing adenosis from adenocarcinoma, 
including: (i) intact basal cell layer, a finding that can be confirmed immunohistochemically 
with antibodies directed against high-molecular-weight cytokeratin 34βE12, (ii) unique 
immunophenotype of many of the basal and spinde cells in the stroma, including abundant 
S100 protein and smooth muscle actin (SMA) reactivity, as well as structural characteristics 
of myoepithelial cells, (iii) cellular spindle cell stroma, (iv) variably thickened basement 
membrane and (v) absence of significant cytological atypia. (Bostwick et al., 1994; Collina et 
al., 1992; Grignon et al., 1992; JonesC et al., 1991; Cheng & Bostwick, 2010; Sakamoto et al. 
1991; Young & Clement, 1987 ; Young & Clement, 1990). Sclerosing adenosis differs from 
AAH by displaying myoepithelial features of the basal cells and an exuberant stroma of 
fibroblasts and loose ground substance (Bostwick et al., 1994). 
5. Lesion Suspicious for Cancer (LSC) 
As a result of the limited quantity of tissue sampled in prostate biopsies, there is the 
probability of finding a lesion that raises diagnostic confusion. There may be lesions 
suspicious for but not conclusive of malignancy. These lesions are small and have a wide 
diversity of architectural and morphological features. Vis proposed the terminology 
“prostate biopsy suspicious for malignancy” to classify these lesions (Vis et al., 2001). 
However, histology reports should be unequivocal and as concise as possible and vague 
diagnoses should not lead to unnecessary biopsy with its associated morbidities.  
The controversial diagnostic term “atypical small acinar proliferation” (ASAP) is no longer 
considered acceptable. It is not considered a diagnostic entity as it can only be diagnosed on 
needle biopsies and not in prostatectomy specimens. The term ASAP has been replaced by 
the term “lesion suspicious for cancer” (LSC), as the prostate lesion lacks sufficient criteria to 
call it a carcinoma. LSC (fig. 1, 2) has gained acceptance as a legitimate way for pathologists 
to describe minute foci of small prostatic acini that raise the suspicion of carcinoma but that 
fail to attain the requisite diagnostic threshold for carcinoma (Fadare et al., 2004).  
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Fig. 1. An accumulation of a few atypical prostatic glands with amphophilic cytoplasm and 
nuclear enlargement. Compare with benign adjacent glands. This field is consistent with 
either atypical small prostate gland proliferation or limited prostate adenocarcinoma. (HE × 
200) 
 
Fig. 2. Atypical cribriform gland at the periphery of a biopsy. Differential diagnosis between 
HGPIN and cribriform invasive adenocarcinoma may be impossible. 
Studies have demonstrated that LSC is diagnosed in 1.5% to 9% of prostatic biopsies and 
that it predicts definite prostate cancer in about 45% of repeat biopsies (Iczkowski et al., 
1997; Iczkowski et al., 1998; Iczkowski & Bostwick, 2000; Iczkowski et al., 2002). Since 1997, 
there have been efforts to stratify risk in cases of LSC into three categories: likely benign, 
uncertain, and likely carcinoma (Iczkowski et al., 1997). No single pathologic feature of LSC 
appeared to increase the likelihood for subsequent cancer (Iczkowski et al., 1998; Iczkowski 
& Bostwick, 2000; Iczkowski et al., 2002; Scattoni et al., 2005). The mean MIB-1 proliferation 
index of LSC was significantly higher than in benign prostatic tissue and did not differ from 
that of low-grade carcinoma. 
LSC continues to be associated with a high risk of prostate cancer and requires a repeat 
biopsy with the extended peripheral zone biopsy scheme (Moore et al., 2005). Sampling 
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should include multiple sites in the prostate, as in 40% of patients; cancer was in different 
sites from the initial LSC site. The detection rate was lower for patients with a larger 
prostate than those with a smaller prostate (Scattoni et al., 2005). Hence, patients with LSC 
should be followed up and undergo repeat biopsy. The role of radical prostatectomy for 
LSC is not clear, although Brausi advocated that prostatectomy could be the treatment of 
choice in young men with LSC (Brausi et al., 2004). 
6. PIN 
6.1 Epidemiology of PIN 
Epidemiological studies have demonstrated the presence of PIN in men as early as the 
fourth decade of life and showed that the incidence and extent of PIN increased with age 
(Sakr et al., 1993). It has been postulated that PIN pre-dates the onset of prostate cancer by 
5–10 years (Sakr et al., 1993). In several autopsy and surgical series, PIN was identified in 
60% to 90% of prostates harboring carcinoma and was often close to its presumed invasive 
equivalent (Qian et al., 1997). Studies showed that PIN was present in 82% of step-sectioned 
autopsy prostates with cancers, but in only 43% of benign prostates from patients of similar 
age (Vis & Van Der Kwast, 2001). Qian found that 86% of a series of 195 whole-mount 
radical prostatectomies contained HGPIN, usually within 2 mm of the cancer (Qian et al., 
1997). 
In the United States, 1.300.000 prostate biopsies are performed annually to detect 230.000 
new cases of prostate cancer (Joniau et al., 2007; Steiner, 2003). There are approximately 
115.000 cases of isolated HGPIN diagnosed each year, representing an estimated 9% of 
prostate biopsies (Steiner, 2003). The incidence of HGPIN in biopsies ranges from 1.5% to 
16.5%, with an average of 6% (Bostwick et al., 1995; Epstein, 2002). The different incidence of 
HGPIN in published studies derives from differences in defining HGPIN and in the number 
of patients. 
The most likely explanation to account for the variation in incidence of PIN is interobserver 
reproducibility (Sakr, 1995). Those pathologists who use a lower threshold to define 
prominent nucleoli will have a higher incidence of HGPIN. Other plausible explanations for 
the variation in reported incidence of HGPIN relate to the fixative used and to differences in 
sampling. Furthermore, the variations from one institution to another can be attributed to 
variation in the population study, the indications for biopsy, and the biopsy compliance 
rates. The site of the prostate biopsied, the number of biopsies taken, and the quality and 
processing technique of the biopsy cores can also influence the incidence of PIN.  
HGPIN starts in young individuals and increases with age in Caucasians and African-
Americans, but is more prevalent in the latter (Epstein, 1995; Sakr et al., 1996). HGPIN in 
African-Americans precedes HGPIN in Caucasians by approximately a decade (Epstein, 
1995). A more extensive form of HGPIN with multifocal or diffuse involvement of the 
glands appears at a younger age in African-Americans in comparison with Caucasians (Sakr 
et al., 1996). The replication of the association of chromosome 8q24 variants with increased 
prostate cancer risk in Tobago men and the higher frequency of the risk alleles in controls in 
populations of African ancestry further strengthens the possible role of this genomic region 
in the disproportionate higher burden of prostate cancer in men of African ancestry (Sakr et 
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al., 1996). It has also been shown that prostate cancer grows more rapidly in black than in 
white men and/or earlier transformation from latent to aggressive prostate cancer occurs in 
black than in white men (Powell et al., 2010).  
6.2 Molecular biology of PIN 
The development of PIN is characterized by increased expression of several biomarkers that 
influence the proliferative potential of the dysplastic prostatic cells. Studies of potential 
biomarkers, such as growth factors, growth factor receptors, oncogene products, 
glycosylated tumor antigens, and other biomarkers in PIN, are difficult because these 
lesions are focal. 
Unlike the premalignant polyps of the colon, it is difficult to obtain relatively pure 
preparations of PIN. One approach, to microdissect areas of PIN, is tedious and still may 
produce results contaminated by surrounding stroma and histologically normal epithelium. 
In addition, this technique does not allow differentiation of biomarker expression among the 
various components (basal versus luminal) of the dysplastic gland or duct.For these reasons, 
immuno - histochemical techniques as well as fluorescence in situ hybridization (FISH) is 
perhaps best suited for the assessment of biomarker expression in PIN.  
FISH analysis has demonstrated strong expression of epidermal growth factor receptor 
(EGFr) mRNA in PIN (Myers & Grizzle, 1996). The c-erbB-2 gene product (p185erbB-2) is a 
transmembrane receptor that demonstrates significant homology to EGFr. Moderate-to-
strong immunoreactivity for p185erbB-2 was noted in the luminal as well as the basal cells 
of PIN lesions. This immunostaining was frequently equivalent in pattern and intensity to 
that of adjacent malignant cells. The pattern of expression was typically coarse cytoplasmic 
immunoreactivity. Increased expression of the growth factor-related receptors p185erbB-2 
and p180erbB-3, as well as the product of the c-met protooncogene (a transmembrane 
tyrosine kinase receptor that binds the mitogen hepatocyte growth factor/scatter factor), is 
frequently detected in the dysplastic luminal cells and in malignant cells of the prostate 
(Myers & Grizzle, 1996). Mutation of the p53 gene in PIN may precede the development of 
highly aggressive prostate cancer (Myers & Grizzle, 1996). The expression of the nm-23H1 
gene product is strongly expressed in dysplastic and malignant prostatic cells (Myers & 
Grizzle, 1996). 
It has been demonstrated that expression of the proliferative markers Ki-67 and proliferating 
cell nuclear antigen (PCNA) in PIN is increased as compared to benign prostatic epithelium 
(Myers & Grizzle, 1996). Increased PCNA expression also has been detected in the nuclei of 
stromal and endothelial cells adjacent to PIN (Myers & Grizzle, 1996). This may be 
associated with the observation of a higher density of blood vessels in the vicinity of PIN 
lesions. In contrast to the enhanced expression of the biomarkers associated with 
proliferation, decreased expression of prostate specific antigen (PSA), prostate acid 
phosphatase, and Leu 7 by dysplastic luminal cells is indicative of an impairment of the 
process of cellular differentiation (Myers & Grizzle, 1996). Bostwick demonstrated a decrease 
in the expression of neuroendocrine markers (neuron-specific enolase, serotonin, 
chromagranin, and human chorionic gonadotropin) in PIN. Aberrant glycosylation as well 
as inappropriate expression of glycosylated tumor antigens was demonstrated by enhanced 
binding of the lectin Ulex europaeus and by increased expression of tumor-associated 
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glycoprotein 72 and the Lewis Y antigen (Myers & Grizzle, 1996). Enhanced expression of 
proteolytic enzymes, such as cathepsin D and the 72-kD form of collagenase IV, by 
dysplastic cells may represent an integral event in the development of invasive prostate 
cancer (Boag & Young, 1994). Moderate-to-strong immunoreactivity for fatty acid synthetase 
was also detected in PIN (Swinnen et al., 2002). 
In HGPIN, studies have demonstrated notable loss of the three critical signaling components 
of the apoptotic action of transforming growth factor-┚; that is, the transmembrane receptor 
II (T┚RII), the key cell cycle inhibitor p27Kip1, and the protagonist downstream Smad4 
receptor-activated protein (Zeng & Kyprianou, 2005). Quantitative evaluation of the 
apoptotic index revealed significantly less value in HGPIN when compared with adjacent 
areas of benign prostatic hyperplasia (Zeng & Kyprianou, 2005). Apoptotic profiling of 
HGPIN may contribute to a better understanding of factors that play a role in deregulated 
prostate growth (Zeng & Kyprianou, 2005). 
Prostate carcinogenesis is the result of the accumulation of multiple genetic changes. The 
most frequently found chromosomal anomalies are overexpression on chromosomes 7p, 7q, 
and 8q, and inactivation on chromosomes 8p, 10q, 13q, 16q, and 18q (Joniau et al., 2005). 
Inactivation of tumor suppression genes, such as NKX3-1 (8p) and PTEN (10q), and 
overexpression of oncogenes, such as c-myc (8q), play an important role in PIN and the 
initiation of prostate cancer (Qian et al 1995). These findings support the multi-step theory 
in which PIN is considered a precursor lesion of prostate cancer. 
6.3 Similarities between PIN and prostate cancer 
The frequency and extent of PIN lesions increase with age, and this is similar to the increase 
in diagnosis of prostate cancer (Joniau et al., 2005). HGPIN is found significantly more 
frequently in prostates with cancer (McNeal & Bostwick, 1986). PIN is predominantly 
located in the peripheral zone of the prostate, the area in which most clinically important 
prostate cancers are found, and PIN, like prostate cancer, is often multifocal ( Joniau et al., 
2005). In an autopsy study, HGPIN was found in 63% of cases solely in the peripheral zone; 
in 36%, in the peripheral and transition zone; and in 1%, solely in the transition zone 
(Haggman et al., 1997). These findings are similar to the zonal distribution of prostate 
cancer.  
Several genotypic and phenotypic studies have indicated that there are remarkable 
morphological, molecular, and biochemical similarities between PIN and prostate cancer 
(Vis & Van Der Kwast, 2001). Molecular abnormalities in PIN are mostly intermediate 
between benign gland and cancer, reflecting an impairment of cell-differentiation and 
regulatory control (Bostwick, 1999). PIN is characterized by cellular crowding and 
stratification. There is inequality in cell and nuclear size. Hyperchromatism is frequently 
seen with an enlarged nucleus, often containing prominent nucleoli lines. These changes are 
also seen in Gleason grade 1–4 prostate cancer (Bostwick et al., 1998). Biochemically, the 
cells of PIN show changes in the cytoskeletal proteins, secretory proteins, and nuclei that are 
shared with established prostate malignancies.  
Prostate cancer and HGPIN have similar proliferative and apoptotic indices (Bostwick et al., 
1998). Mitotic figures and apoptotic bodies increase progressively from nodular hyperplasia 
to HGPIN (Bostwick et al., 1998). During the malignant transformation of PIN, the basal cell 
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layer loses its proliferative function, which is transferred to secretory luminal cell types, as 
demonstrated by Bonkhoff (Bonkhoff, 1996). Moreover, there is a progressive increase in the 
number of apoptotic bodies from nodular hyperplasia through PIN to prostate cancer 
(Bostwick et al., 1996). Greater cytoplasmic expression of bcl-2 is observed in PIN and cancer 
than in benign and hyperplastic epithelium (Bostwick et al., 1996). Two members of the 
platelet-derived growth factor (PDGF) peptide family, PDGF-A and PDGF-┙, are up-
regulated in PIN and prostate cancer compared with benign prostatic hyperplasia; BPH 
(Bostwick et al., 1996). Similarly, there is up-regulation of cathepsinD in PIN and prostate 
cancer; this autocrine mitogen, which has been studied extensively in other organs as a 
marker of invasion, correlates with tumor grade and DNA ploidy status in prostate cancer 
(Bostwick et al., 1996). 
Histologically, the atypia observed in HGPIN is virtually indistinguishable from that of 
prostate cancer except that in HGPIN the basal membrane is still intact (Sakr et al., 1999). As 
HGPIN progresses, the likelihood of basal cell layer disruption increases. In HGPIN, the 
basal cell layer is disrupted or fragmented as demonstrated by high-molecular-weight 
cytokeratin immunolabeling. In prostate cancer, there is a complete loss of the basal cell 
layer. Both in PIN and prostate cancer, collagenase type IV expression is increased 
compared to normal prostate epithelium; this enzyme is responsible for basal membrane 
degradation and thus facilitates invasion (Bostwick et al., 1996). PIN and prostate cancer 
share several nuclear properties, such as amount of DNA, chromatin texture, chromatin 
distribution, nuclear perimeter, diameter, and nuclear abnormalities (Baretton et al., 1994).  
Several genetic changes encountered in prostate cancer cells can be found in PIN lesions 
(Bostwick et al., 1996). Allelic loss is common in PIN and prostate cancer (Sakr et al., 1999). 
The frequent 8p12-21 allelic loss commonly found in prostate cancer is also found in 
microdissected PIN. Other examples of genetic changes found in prostate cancer that 
already exist in PIN include loss of heterozygosity at 8p22, 12pter-p12, and 10q11.2 and gain 
of chromosomes 7, 8, 10, and 12. Alterations in oncogene bcl2 expression and RER+ 
phenotype are similar for PIN and prostate cancer (Baltaci et al., 2000). As in prostate cancer, 
there is also evidence of aneuploidy and an increase in microinvascular density, both 
frequently regarded as evidence of aggressiveness in PIN (Montironi et al., 1993). 
6.4 LGPIN 
In LGPIN (Fig. 3), secretory cells of the lining epithelium proliferate and “pill up” with 
irregular spaces between them (Bostwick, 2000 ; Newling, 1990). The nuclei are enlarged, 
vary in size, have normal or slightly increased chromatin content, and possess small or 
inconspicuous nucleoli (Zeng & Kyprianou, 2005). More prominent nucleoli, when 
observable, comprise less than 10% of dysplastic cells. The basal cell layer normally 
surrounding secretory cells of ducts and acini remains intact. In LGPIN, only 0.7% of 
reported cases reveal evidence of basal cell layer disruption (Newling, 1999).  
LGPIN is rather difficult to recognize, as it shares common features with normal and 
hyperplastic epithelium (Bostwick, 2000; Newling, 1999). The most common issue that may 
lead in some cases to discrepant diagnoses between LGPIN and HGPIN is the definition of 
“prominent” with regard to nucleolar enlargement and visibility. 
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It has been suggested that LGPIN should not be commented on in diagnostic reports 
(Epstein, 2002). Firstly, pathologists cannot reproducibly distinguish LGPIN from benign 
prostate tissue (Epstein et al., 1995). Secondly, when LGPIN is diagnosed on needle biopsy, 
these patients are not at greater risk of having prostate cancer on repeat biopsy (Keetch, 
1995). 
The distinction between HGPIN and LGPIN is based primarily on the extent of cytological 
abnormalities (prominence of the nucleoli) and secondarily on the degree of architectural 
complexity (Goeman et al., 2003; Weinstein & Epstein, 1993). Immunostaining studies of 
microvessel density may help to differentiate HGPIN from LGPIN (Sinha et al., 2004). 
 
Fig. 3. Papillary structures within a large hyperplastic prostate gland. Minimal nuclear 
atypia. (HE × 200) 
6.5 HGPIN 
6.5.1 Why HGPIN? 
PIN was initially divided into three different grades (I–III), which now are reduced to the 
abovementioned LGPIN for PIN I, and HGPIN for PIN II and III. HGPIN includes PIN II 
and III for two reasons. Firstly, there was a great deal of inter-observer variability in the 
distinction between PIN II and III (Epstein et al., 1995). Secondly, the finding of PIN II or III 
on needle biopsy was associated with the same risk of prostate cancer on subsequent biopsy 
(Weinstein & Epstein, 1993).  
6.5.2 Histology of HGPIN 
In HGPIN, uniform morphologic abnormalities are detectable (Vis & Van Der Kwast, 2001). 
Cells have large nuclei of relatively uniform size, and possess prominent nucleoli that are 
similar to those of cancer cells (fig. 4, 5). Regarding cytological features, the acini and ducts 
are lined by malignant cells which are uniformly enlarged with an increased 
nuclear/cytoplasmic ratio, and with less variation in nuclear size in comparison to LGPIN. 
In HGPIN, at least 10% of cells demonstrate prominent nucleoli similar to those of 
carcinoma cells, and the majority of cells show coarse clumping of the chromatin which may 
be accentuated along the nuclear membrane (Vis & Van Der Kwast, 2001). The expanded 
nuclear chromatin area probably explains the darker “blue” appearance of the lining which 
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characterizes HGPIN at low power microscopic examination. Nuclei toward the centre of 
the gland tend to have blander cytology than peripherally located nuclei. 
 
 
 
Fig. 4. HGPIN tufted pattern and adjacent carcinoma (with an adequate number of small 
malignant glands). Small atypical glands are too numerous to represent outpouchings of 
HGPIN. (HE × 200) 
6.5.3 Patterns of HGPIN 
There are four architectural patterns of HGPIN: tufting, micropapillary, flat and cribriform, 
based on the arrangement of the cells within pre-existing ducts or glands (Vis & Van Der 
Kwast, 2001). Tufting HGPIN is by far the most common pattern (present in 97% of all 
HGPINs) followed by micropapillary, flat, and cribriform patterns (Yamauchi et al., 2006). 
In the flat pattern, nuclear atypia is evident without significant architectural changes. In the 
tufting pattern, nuclei become more pilled up, and undulating mounds of cells are formed. 
Columns of atypical epithelial cells typically lacking fibrovascular cores characterize the 
micropapillary pattern. In the cribriform pattern, more complex architectural features, such 
as a “Roman bridge” and cribriform formation, are encountered.  
Patients with HGPIN in only one initial biopsy or a predominant flat/tufting pattern clearly 
have less risk of cancer being found in subsequent biopsies compared to patients with 
HGPIN in more than one initial biopsy. Furthermore, a micropapillary and/or cribriform 
pattern are correlated with a greater risk for development of prostate cancer (Joniau et al., 
2005). 
Unusual subtypes of HGPIN include PIN with signet-ring morphology and neuroendocrine 
cells with either Paneth cell-like or small-cell morphology (Bostwick et al., 1993; Vis & Van 
Der Kwast, 2001). Intraductal HGPIN, in prostates with established cancer, has been 
associated with high tumor volumes, poorly differentiated tumor components, and a higher 
progression rate after radical prostatectomy than prostate cancers without these coexisting 
proliferations (Cohen et al., 2000; McNeal & Bostwick, 1986). Hence, a separate histological 
entity was proposed, namely, intraductal carcinoma of the prostate, which would be 
distinguished from HGPIN. 
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6.5.4 HGPIN and prostate cancer 
HGPIN is the most likely precursor of prostatic adenocarcinoma, according to current 
literature (Dovey et al., 2005; Gaudin et al., 1997; Joniau et al., 2005; Lefkowitz et al., 2002; 
Pacelli & Bostwick, 1997; Powell et al., 2010; Singh et al., 2009; Vis & Van Der Kwast, 2001). 
The expression of various biomarkers in HGPIN is either the same as with prostate cancer or 
intermediate between prostate cancer and benign prostate tissue. The cytological changes 
are characterized by prominent nucleoli in a substantial proportion (≥5%) of cells, nuclear 
enlargement and crowding, increased density of cytoplasm, and anisonucleosis (Vis & Van 
Der Kwast, 2001). Ploidy seems not to discriminate between HGPIN and infiltrating cancer 
(Baretton et al., 1994). Also, studies reveal consistent down-regulation of epithelial cell 
adhesion molecules and transmembrane proteins in PIN (Vis & Van Der Kwast, 2001). This 
is accompanied by up-regulation of enzymes responsible for degradation of the extracellular 
matrix.  
Unlike in prostate cancer, incomplete disruption of the basal cell layer can be shown by 
34┚E12 cytokeratin immunostaining (Vis & Van Der Kwast, 2001). In HGPIN, more than 
50% of abnormal cells are seen to have a disrupted basal cell layer in the acini. 
Immunohistochemistry is usually not helpful since the lack of a basal cell layer in only a few 
cribriform or small glands is not sufficient for the diagnosis of cancer. However, in cases 
where many glands are totally immunonegative for high-molecular-weight cytokeratin, 
these foci may be diagnostic of cancer. Cases where some of the glands show the expected 
patchy basal cell layer of PIN and a few, morphologically identical glands are negative for 
high-molecular-weight keratin should still be diagnosed as HGPIN. In rare cases when 
sperm can be identified in the glandular lumen, the diagnosis of PIN is favored because only 
PIN glands are able to communicate with the main prostatic glands that contain sperm; 
malignant invasive glands cannot retain their continuity with main prostatic glands (Vis & 
Van Der Kwast, 2001).  
In cases of HGPIN with neighboring small atypical glands, the possibility of coexistent 
invasive carcinoma should be examined (Vis & Van Der Kwast, 2001). When the latter are 
few, the issue is whether the small glands represent outpouchings or tangential sections of 
the adjacent HGPIN or whether they represent microinvasive cancer. When these small 
atypical glands are too many or too crowded to be outpouchings or tangential sections of 
the HGPIN glands, then the diagnosis of invasive carcinoma can be made (Bostwick et al., 
1996).  
6.6 Differential diagnosis of PIN 
Histologically, PIN can be confused with several benign entities as well as with ductal and 
acinar adenocarcinoma (fig. 5) of the prostate (Epstein et al., 2002). Benign conditions 
include prostate central zone hyperplasia, since glands within the central zone at the base of 
the prostate are complex and large with many papillary infoldings and clear cell cribriform 
hyperplasia, which consists of crowded cribriform glands with clear cytoplasm (Vis & Van 
Der Kwast, 2001; Joniau et al., 2005). Both these entities lack significant nuclear atypia. The 
basal cell layer can display prominent nucleoli but secretory cells can be recognized. 
Cytologically atypical basal cell hyperplasia usually forms small solid nests of atypical basal 
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cells, mainly in the central zone; these are inconsistent with PIN, which affects medium- or 
large-sized glands, mainly in the peripheral zone of the prostate (Vis & Van Der Kwast, 
2001). In any case, basal cells can be easily identified by immunohistochemistry either with 
antibodies against high-molecular-weight cytokeratins (cytoplasmic staining pattern) or 
against p63 (nuclear staining pattern). 
 
 
 
 
 
 
 
Fig. 5. Complex atypical gland with prominent nucleoli and perineural invasion. Gleason 
pattern 3 of cribriform adenocarcinoma. Note the coexistent microacinar cancerous pattern 
on the bottom right. (HE × 200) 
With regard to malignant conditions, cribriform acinar adenocarcinoma can be 
discriminated from cribriform HGPIN when a sufficient number of cribriform glands totally 
lack basal cells (Vis & Van Der Kwast, 2001). Furthermore, in cribriform carcinoma, 
sometimes the appearance of foci of back-to-back glands, rather than true cribriform 
formations, is evident.  
Ductal adenocarcinomas of the prostate may demonstrate a patchy basal cell layer (like 
PIN), but they develop in the transition zone. They may develop true papillary fronts with 
fibrovascular cores (in contrast to micropapilary PIN). Ductal adenocarcinoma glands are 
larger, may contain back-to-back glands, may show extensive comedonecrosis, and are 
usually fragmented in needle biopsy specimens. 
Finally, the possibility of intraductal carcinoma (fig. 6) should be considered when multiple 
cribriform glands with prominent cytological atypia containing comedonecrosis are 
encountered (Cohen et al., 2000; McNeal & Bostwick, 1986). In these glands, basal cells can 
be identified, though this lesion should be distinguished from HGPIN since it appears to be 
a late event in prostate gland carcinogenesis and warrants immediate therapy. 
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Fig. 6. Many large atypical cribriform glands with extensive comedonecrosis. Retention of 
basal cell layer remnants would be consistent with intraductal carcinoma rather than 
HGPIN. (HE × 200) 
6.7 Clinical markers of PIN 
6.7.1 PSA 
PIN lesions do not contribute to an elevation of serum PSA, PSA density, or a decrease in 
the free-to-total PSA ratio (Alexander et al., 1996; Darson et al., 1999; Ronnett et al., 1993). 
PIN lesions show less expression of PSA in luminal cells, as determined by 
immunohistochemistry, than do benign epithelial glands (Ronnett et al., 1993; Alexander et 
al., 1996). An elevation of PSA should be attributed to the presence of prostate cancer, BPH, 
or concurrent prostatic inflammation rather than to the presence of PIN.  
Immunohistochemical studies show a lower PSA expression in PIN lesions compared to 
benign tissue and prostate cancer (Darson et al., 1999). PSA produced by PIN lesions follows 
the route of least resistance and is excreted in the seminal fluid, whereas cancer forms tissue 
islands without a surrounding basal layer, and PSA diffuses into the blood. 
6.7.2 Potential markers 
Swinnen demonstrated that fatty acid synthetase immunostaining intensity tended to 
increase from LGPIN to HGPIN and prostate cancer (Swinnen et al., 2002). This key enzyme 
in the de novo production of fatty acids enables cancer progression and invasion. Another 
enzyme, alpha-methylacyl coenzyme A racemase (AMARC), which plays a key role in the 
beta-oxidation of fatty acids, is rarely expressed in benign prostatic tissue, in contrast to PIN 
and prostate cancer (Rubin et al., 2002). A statistically significant association of this 
biomarker with the risk of prostate cancer is yet to be revealed (Hailemariam et al., 2011). 
A80, a membrane-bound glycoprotein that is related to exocrine differentiation, may be 
useful in detecting residual and/or recurrent prostate carcinoma after radiation or hormonal 
therapy (Coogan et al., 2003). Benign glands are generally negative for A80 except for 
scattered positive cells in about 15% of glandular hyperplasia (Shin et al., 1989). Coogan 
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demonstrated that A80 immunostaining in prostate cancer, HGPIN, and LGPIN, in 100%, 
92%, and 73% of the examined specimens, respectively (Coogan et al., 2003). Markers 
including kallikrein-related peptidase 2 (KLK2), early prostate cancer antigen (EPCA), 
PCA3, hepsin, prostate stem cell antigen are under investigation for the early diagnosis and 
management of prostate cancer (Darson et al., 1997; Sardana et al., 2008). PCA3 is a prostate 
specific, non-protein coding RNA that is significantly over expressed in prostate cancer, 
without any correlation to prostatic volume and/or other prostatic diseases like prostatitis. 
Recent studies have shown the potential of PCA3, in correlation with other markers, to be 
used as a prognostic marker for prostate cancer (Bourdoumis et al., 2010). 
6.8 Management of PIN 
6.8.1 Repeat prostate biopsy 
As a consequence of programs for the early detection of prostate cancer, the number of 
biopsies performed and specimens evaluated has increased substantially. False-positive 
results may strongly influence a man’s quality of life through unnecessary psychological 
stress, unnecessary treatment, and treatment-associated morbidities. Furthermore, for 
medico-legal reasons, it is obvious that biopsy false-positive results should be minimized. 
Currently, the consensus is that the finding of focal atrophy, PAH, AAH, or LGPIN on 
needle biopsy or in TURP material for BPH should not lead to any diagnostic follow-up (Vis 
& Van Der Kwast, 2001). However, the finding of HGPIN on needle biopsy indicates a field 
effect by which the entire prostate is at higher risk of harboring cancer (Langer et al., 1996).  
The decisions for diagnostic follow-up in men with PIN should take into account the 
patient’s age, physical status, and co-morbidities. In men developing HGPIN in the eighth 
decade, knowing that the development of symptomatic prostate cancer will probably occur 
only after 10 years, a policy of watchful waiting should be recommended.( Ravery V , 2009 ; 
Vis AN & Van Der Kwast TH , 2001 ) Men who may not potentially benefit from curative 
treatment or early hormonal therapy should not undergo follow-up biopsy.  
When more extensive repeat biopsy is performed, the likelihood of detecting prostate cancer 
is increased. If isolated HGPIN is detected in a 12-core biopsy protocol, the cancer incidence 
in the immediate 12-core repeat biopsy will be only 2% to 3% (Lefkowitz, 2002). In contrast, 
in repeat biopsies following initial sextant or octant biopsies, the cancer detection rate is 27–
30% (Lefkowitz, 2002). However, taking too many biopsies can increase the risk of detecting 
too many clinically insignificant cancers and can lead to overtreatment (Joniau et al., 2005). 
Authors have proposed an 8-biopsy regimen, which clearly outperformed the sextant 
regimen in cancer detection (Joniau et al., 2005; Lefkowitz, 2002).  
When follow-up biopsies are performed in men with foci of isolated HGPIN, the site of 
prostate cancer may not be the same site that raised the suspicion of concurrent carcinoma 
(Bostwick et al., 1995). The finding of HGPIN after TURP (2.8%-33%) also appears to place 
men at a higher risk of harboring cancer, although there are few studies on this topic 
(Gaudin et al., 1997; Pacelli & Bostwick, 1997). It is reasonable to perform needle biopsies on 
patients, especially younger men, who have HGPIN after TURP.  
It has been demonstrated that patients with a flat or tufting HGPIN pattern on initial biopsy 
clearly have less risk of cancer being found in subsequent biopsy (20%), in comparison with 
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patients with micropapillary or cribriform pattern, who have a relative risk of 70% (Chan & 
Epstein, 1999). The isolated finding of HGPIN in the cystoprostatectomy specimen has no 
clinical implications, and the prognosis of the patient is determined by the initial indication 
(e.g. invasive bladder cancer) for surgery.  
The jury is still out concerning the best repeat biopsy strategy following the diagnosis of PIN 
on initial prostate biopsy. The length of the interval still needs to be established in large 
prospective studies (Joniau et al., 2005).  Repeat biopsy six weeks after the initial biopsy has 
led to the diagnoses of prostate cancer in 9% of cases with isolated HGPIN (Chan & Epstein, 
1999; Ellis & Brawer, 1995; Kronz et al., 2001; O’Dowd et al., 2000). The risk for finding 
prostate cancer in repeat biopsies seems to increase with the length of the biopsy interval. 
Age, PSA, and HGPIN were independent predictors for prostate cancer in repeat biopsies, 
with HGPIN providing the highest risk ratio (Chan & Epstein, 1999; Langer et al., 1996; Sakr 
et al., 1996). Most urologists recommend follow-up biopsy after 6–12 months, followed by 
regular PSA monitoring and repeat biopsies as indicated (Shepherd et al., 1996). Men within 
screening settings who are diagnosed with isolated HGPIN should be followed at regular 
intervals, and if clinical suspicion persists, the biopsy should be repeated (Ellis & Brawer, 
1995; Kronz et al., 2001; Shepherd et al., 1996). The finding of intraductal HGPIN on initial 
biopsy needs further investigation with repeat biopsy, because this lesion is related to 
potentially aggressive cancer.  
6.8.2 Chemoprevention 
Examples of treated premalignant lesions include cervical intraepithelial neoplasia, ductal 
CIS (carcinoma in situ) of the breast, adenomatous polyps of the colon, and Barrett’s 
esophagus (Sporn, 1999). The American Association for Cancer Research designates 
intraepithelial neoplasia an important target for chemoprevention (O’Shaughnessy et al., 
2002). As HGPIN precedes the development of prostate cancer by several years and is easy 
identifiable, it is a candidate for chemoprevention. Chemoprevention means the 
administration of drugs or agents aimed at preventing the initiation and progression of 
cancer. A number of potential preventive agents have been investigated in patients with 
HG-PIN, including hormones (flutamide, finasteride, leuprolide acetate) and antioxidants 
such as lycopene, selenium, and catechins. An association beween the E-cadherin/catenin 
complex and high-grade prostate cancer has been proved and the therapeutic potential of 
integrin antagonists is being evaluated by ongoing clinical trials with promising results 
(Drivalos et al., 2011). One of the most promising chemoprevention drugs is the selective 
oestrogen receptor modulator toremifene citrate (Ravery, 2009). Recognizing the slow 
growth rate of prostate cancer and the considerable amount of time needed in animal and 
human studies for adequate follow-up, the noninvasive precursor lesion PIN is a suitable 
intermediate histological marker to indicate high likelihood of subsequent prostate cancer. 
HGPIN offers promise as an intermediate endpoint in studies of chemoprevention of 
prostate cancer (Montironi et al., 1999). Hence, HGPIN is a suitable intermediate histological 
marker to indicate subsequent likelihood of cancer and it may be worth monitoring young 
men with a high risk of developing HG-PIN in the future as potential targets for 
chemoprevention rather than focusing only on chemoprevention in the high-risk HG-PIN 
patient group (Ravery, 2009). 
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Anti-androgens (e.g. fluatamide) induce the regression of prostatic epithelium by enhancing 
apoptosis, suppressing proliferative activity, and inhibiting angiogenesis in BPH, PIN, and 
prostate cancer (Montironi et al., 1994). PIN is ablated by androgen deprivation therapy, as a 
result of accelerated apoptosis with subsequent exfoliation of cells into the glandular lumens 
(Montironi et al., 1994). Studies have documented that angiogenesis in the surrounding 
stroma of HGPIN glands is severely decreased via suppression of vascular endothelial 
growth factor (VEGF) production after androgen deprivation therapy (Papatsoris & 
Papavassiliou, 2001). A marked decrease in the extent and prevalence of HGPIN occurs in 
patients treated with anti-androgens in comparison to untreated patients (Bostwick & Qian, 
1999). It has been suggested that anti-androgens might halt or reverse the process of 
carcinogenesis and prevent the transition of HGPIN to overt prostate cancer (Bostwick & 
Qian, 1999; Lieberman et al., 2001; Montironi et al., 1994; van der Kwast et al., 1999). The 
observed morphological changes (cytoplasmic clearing, prominent glandular atrophy, 
decreased ratio of glands to stroma) are reversible, and HGPIN lesions recover rapidly. 
However, it is unclear whether the histopathologic changes of anti-androgen treatment are 
clinically important (Lieberman et al., 2001; van der Kwast et al., 1999). Yamauchi 
demonstrated that the anti-androgen bicalutamide permitted the persistence of PIN after 
effective chemoprevention of  microscopic prostate cancer in a rat model (Yamauchi et al., 
2006). Moreover, there is a risk for amplification of the androgen-receptor (AR) gene in 
androgen-deficient conditions, as in cases of hormone-refractory prostate cancer (Koivisto et 
al., 1999). The blockage of 5-alpha reductase with finasteride does not seem to have any 
effect on the incidence of PIN (Yang et al., 1999). In addition to the above, the role of 
Ras/mitogen-activated protein kinase (MAPK) in prostate cancer, as well as the therapeutic 
potential of Ras/map inhibitors are currently under investigation (Papatsoris et al., 2007). 
Furthermore, it has been demonstrated that men with no evidence of prostate cancer on 
initial biopsy who were pretreated with finasteride had a significantly greater prostate 
cancer detection rate at one year than had men in the control group; 30% versus 4% (Cote et 
al., 1998).  
Besides anti-androgens, other drugs (e.g. anti-angiogenics agents) and nutritional 
supplements (e.g. vitamin D, selenium) have been applied in ongoing chemoprevention 
trials (Montironi et al., 1994). In a prospective trial evaluating the effects of selenium-vitamin 
E-isoflavonoid supplement in 100 men with isolated HGPIN in octant biopsies, PSA 
decreased in a large subgroup (64%). In this subgroup, the overall risk of detecting cancer 
was 24.5%, compared to 55.6% in a smaller subgroup of patients in whom the PSA 
continued to rise under supplements (Joniau et al., 2005). Bettuzzi administered green tea 
catechin (GTC) in men with HGPIN and demonstrated that GTC is safe and very effective 
(Bettuzzi et al., 2006). In particular, after one year, only one prostate cancer was diagnosed 
among the 30 GTC-treated men (3%), whereas nine cancers were found among the 30 
placebo-treated men (30%).  
Studies suggest that administration of the nerve-growth factor (NGF) induces a reversion of 
the androgen-independent / androgen-receptor negative prostate cancer cell lines to a less 
malignant phenotype, which raises thoughts for a new perspective in prostate cancer 
therapy (Papatsoris et al., 2007). Moreover, deregulation of the IGF-1/IGF-1-receptor axis 
has been liked to progression of prostate cancer to androgen independenace and new 
therapeutic possibilities are currently under research (Papatsoris et al., 2005).  
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The ideal agent and duration of therapy remains to be defined. The selective alpha-estrogen 
receptor modulator toremifene was investigated in HGPIN. Studies using the transgenic 
adenocarcinoma of mouse prostate model (TRAMP) and this anti-estrogen demonstrated a 
reduction in the incidence of HGPIN and prostate cancer, along with an increase in animal 
survival (Raghow et al., 2002). The statistically significant reduction in the incidence of 
prostate cancer and the tolerability profile support toremifene’s promise as a 
chemopreventive agent. 
Although small, high-risk population trials will remain the key to the early evaluation of 
novel chemoprevention agents, large-scale, population-based clinical trials will still be 
necessary to ensure that valid recommendations are made to men regarding 
chemoprevention. Until the efficacy of chemopreventive agents is confirmed in well-
conducted, randomized, controlled studies, there should be a reluctance to offer 
chemopreventive agents to men with isolated HGPIN on initial biopsy. 
6.8.3 Radical prostatectomy and radiotherapy 
HGPIN is sometimes associated with a PSA above normal levels; in other words, in these 
cases, HGPIN could be regarded as T1c prostate cancer (Newling, 1999). The firm evidence 
that within six months of the first biopsy showing HGPIN, invasive prostate cancer would 
be diagnosed in 60% of the cases has made some urologists offer radical prostatectomy to 
this group of patients (Newling, 1999). Nowadays, radical prostatectomy is not regarded as 
appropriate therapy for the management of patients with HGPIN (Davidson et al., 1995; 
Montironi et al., 2002; Newling, 1999). It seems logical that malignant histological changes 
should be seen before such radical therapy is offered. It has been recently shown that PSA 
and HGPIN focality at biopsy do not enhance cancer predictivity, thus patients who 
underwent prostate biopsy with a HGPIN diagnosis do not seem to need any different 
follow-up rebiopsy strategy than patients with a diagnosis of BPH (Gallo et al., 2008). 
The prevalence and extent of PIN lesions decreases significantly after radiation therapy. 
Following such therapy, PIN retains the typical characteristics of untreated PIN and is 
readily recognized on histopathology (Cheng et al., 1999). The question remains if 
recurrence after radiation therapy is due to the growth of incompletely eradicated tumor or 
progression of incompletely eradicated PIN. 
6.8.4 Potential anti-PIN agents 
a. Anti-Angiogenesis Agents. The changes that occur in HGPIN leading to focal 
carcinoma include neo-angiogenesis; hence, the use of the anti-angiogenesis agent’s 
thalidomide and platelet growth factor 4 could be important therapeutic interventions 
(Papatsoris et al., 2005).  
b. Differentiation Factors. Retinoids and vitamin D analog are known to improve 
differentiation of epithelial cells, including prostate epithelium.The development of 
invasiveness, as seen in HGPIN, is characterized by loss of adhesion facility and 
dedifferentiation with aneuploid nuclear characteristics; these processes may be 
sensitive to retinoids or vitamin D analogs (Papatsoris et al., 2005; Banach-Petrosky et 
al, 2006; Kelloff et al., 1999). Gene therapy and immunotherapy are still experimental in 
prostate cancer and HGPIN. Serial examination of prostate biopsies and subsequent 
prostatectomy specimens may give an indication of the effectiveness of these agents. 
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c. Epigenetic Therapeutics (Histone Deacetylase Inhibitors, Hypomethylating Agents). 
Epigenetic events, such as histone acetylation/deacetylation and aberrant DNA 
methylation, represent crucial steps in prostate cancer development, which cause 
alterations in gene expression (e.g. silencing tumor suppressor genes) without changes 
in the DNA coding sequence (Kopelovich et al., 2003). Epigenetic changes can be 
reversed by the use of small molecules, such as histone deacetylase (HDAC) inhibitors 
and hypomethylating agents. Histones are core protein components of nucleosomes, 
and their acetylation status regulates gene expression. Deacetylated histones are 
generally associated with silencing gene expression (Marks et al., 2001). HDAC 
inhibitors have been shown to induce expression of genes linked to growth inhibition 
and cellular differentiation. Several phase I trials with these agents are ongoing in 
patients with prostate cancer and/or PIN (Sandor et al., 2002).  
A mechanism to switch off tumor suppressor genes is controlled by a chemical modification 
known as DNA methylation, a normal cellular process whereby cytosines in the DNA 
become methylated by the enzyme DNA methyltransferase to give 5-methylcytosine (Kang 
et al., 2004). However, in cancer cells, the methylation process is deregulated, and many 
genes, including tumor suppressor genes, become abnormally methylated at cytosine bases. 
Moreover, it seems that aberrant methylation causes recruitment of HDAC, resulting in a 
more potent transcriptional inhibition of target genes (Patra et al., 2001). Many studies have 
demonstrated epigenetic silencing of crucial genes, for example, AR, PTEN, and RAR┚, 
during prostate carcinogenesis (Yamanaka et al., 2003). Novel hypomethylating agents are 
in various stages of experimental and clinical development. 
7. Epilogue 
Recurrent chromosomal rearrangements have not been well characterized in prostate cancer 
(Papatsoris et al., 2007). Tomlins used a bioinformatics approach to discover candidate 
oncogenic chromosomal aberrations on the basis of outlier gene expression, followed by 
RNA ligase-mediated rapid amplification of cDNA ends and sequencing (Tomlins et al., 
2005). The authors identified recurrent gene fusions of the 5-prime untranslated region of 
TMPRSS2 to two ETS transcription factors, ERG or ETV1, in prostate cancer tissues with 
outlier expression. By using FISH, they demonstrated that 23 of 29 prostate cancer samples 
harbored rearrangements in ERG or ETV1. Cell line experiments suggested that the 
androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS 
family members in prostate cancer. Yoshimoto demonstrated that the occurrence of these 
genetic events, along with Pten haploinsufficiency, in patients with prostate cancer has a 
significant clinical impact (Yoshimoto et al., 2008). Most importantly, the identification of 
ERG as a cooperative initiation event in prostate tumorigenesis suggests that ERG targeted 
therapies, when feasible, may be effective at preventing the transition between HGPIN and 
invasive cancer, while pharmacological manipulation of the PTEN/PI3K/AKT pathway 
may represent a powerful chemopreventive and chemotherapeutic tool in the future (Carver 
et al., 2009). Surprisingly, the above-mentioned translocation was found in about 70–80% of 
prostate cancers, but not in HGPIN. Finally, the diagnosis of prostate cancer on needle 
biopsy has been refined because of the recent discovery of AMARC, which preferentially 
labels prostate adenocarcinoma (Epstein, 2006). Also, in a recent peer review Epstein 
outlined several recommendations when diagnosing PIN or atypical foci suspicious for 
carcinoma in needle biopsies (Epstein & Herawi, 2006).  
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In conclusion, prostate cancer precursor lesions include mainly AAH and PIN (Chrisofos et 
al., 2007). LSC is not considered a precursor lesion of prostate cancer but shares with PIN the 
increased risk of diagnosing a definite cancer in subsequent biopsies. LGPIN should not be 
reported by pathologists due to poor inter-observer reproducibility and a relatively low risk 
of cancer following re-biopsy. The average incidence of HGPIN or LSC on initial needle 
biopsy is 6%. Following the diagnosis of HGPIN, the risk of cancer is not statistically higher 
compared with the risk of cancer following a benign diagnosis. Studies have shown that the 
risk for cancer after HGPIN diagnosis was not higher than the risk reported after diagnosis 
of BPH (Gallo et al., 2008). In contrast, the average risk of cancer following a diagnosis of 
LSC is 40%, and such patients should be re-biopsied within three to six months. Cases 
diagnosed as LSC have the highest likelihood of being changed upon expert review. 
Potential markers of prostate cancer precursor lesions include fatty acid synthetase, 
AMARC, and A80. However, clinical and pathological parameters do not help to stratify 
which men are at greater risk for a cancer diagnosis. Repeat biopsy should include increased 
sampling of the initial precursor lesion and adjacent ipsilateral and contralateral sites, with 
routine sampling of all sextant sites. Radical prostatectomy and radiotherapy are not 
recommended for the management of patients with HGPIN. Until the efficacy of 
chemopreventive agents is confirmed in well-conducted, randomized, controlled studies, 
there should be a reluctance to offer such agents to men with prostate cancer precursor 
lesion on initial biopsy. 
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